Abbott has gotten EU approval for sale of it's new glucose metering system that has a sensor that lasts up to 14 days. It allows you to test as many tests as desired during the day and should be available within the coming weeks in selected countries in Europe. It is unclear how accurate the system is as accuracy data is not publicly available.
Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes
- FreeStyle Libre System eliminates routine finger pricks for glucose measurements1 and requires no finger pricks for calibration
- Available for people living with diabetes in several European markets beginning in the coming weeks
- Advanced Ambulatory Glucose Profile software presents data in a user-friendly, visual chart, enabling productive treatment discussions
September 3, 2014
ABBOTT PARK, Ill., Sept. 3, 2014 — Abbott today announced that it has received CE Mark (Conformité Européenne) for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes. The system eliminates the need for routine finger pricks, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days. In addition, no finger prick calibration is needed—a key differentiator from current continuous glucose monitoring systems. The system will be available in seven countries across Europe in the coming weeks.
Key features of Abbott's FreeStyle Libre System include:
- The system requires no finger prick calibration
- Disposable, water-resistant sensor can be worn on the back of the upper arm for up to 14 days
- Glucose readings can be taken as many times per day as needed or desired, with a painless one second scan
- Each scan provides a current glucose reading, 8-hour history and the direction glucose is heading
- The data generated by the system is designed to provide actionable trends and patterns that may help people determine how to modify food and other behaviors to better manage their diabetes in consultation with their healthcare professionals
For more information see the Abbott Press release.